 BRISBANE, Calif., June 01, 2022 GLOBE NEWSWIRE -- Annexon, Inc. Nasdaq: ANNX, a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that the company will present data from across its complement-targeted pipeline at several upcoming medical meetings. 